{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"19.1","value":"12.3"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"10.3","value":"4.7"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG002","lowerLimit":"3.4","upperLimit":"NA","value":"6.4"},{"groupId":"OG003","lowerLimit":"4.0","upperLimit":"8.0","value":"5.6"},{"groupId":"OG004","lowerLimit":"6.9","upperLimit":"16.4","value":"13.9"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG005","lowerLimit":"16.8","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"5.7","upperLimit":"12.8","value":"8.1"},{"groupId":"OG007","lowerLimit":"1.1","upperLimit":"24.8","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"68"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from first dose of study drug to death due to any cause. OS was calculated using the Kaplan-Meier method.\n\nParticipants who did not die while on study were censored on the date they were last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"MEDIAN","populationDescription":"All treated participants in Phase 1b; Efficacy endpoints were specified to be analyzed by disease type for phase 1b participants only.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to the end of study; maximum time on study in Phase 1b was 35.9 months.","title":"Efficacy: Overall Survival (Phase 1b)","type":"SECONDARY","unitOfMeasure":"months"}